Bank Of America Corp Janux Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 23,541 shares of JANX stock, worth $986,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,541

Previous 43,801 46.25%

Holding current value

$986,132

Previous $469,000 88.91%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $160,661 - $1.01 Million	-20,260 Reduced 46.25%	23,541 $886,000
Q4 2023 Feb 14, 2024	BUY	$5.85 - $11.7 $132,525 - $265,051	22,654 Added 107.13%	43,801 $469,000
Q2 2023 Aug 14, 2023	SELL	$11.08 - $15.92 $28,697 - $41,232	-2,590 Reduced 10.91%	21,147 $251,000
Q1 2023 May 12, 2023	BUY	$11.25 - $22.21 $58,938 - $116,358	5,239 Added 28.32%	23,737 $287,000
Q4 2022 Feb 10, 2023	BUY	$11.1 - $18.26 $37,085 - $61,006	3,341 Added 22.04%	18,498 $243,000

Q3 2022 Nov 14, 2022	SELL	$10.82 - $16.84 $112,106 - $174,479	-10,361 Reduced 40.6%	15,157 $206,000
Q2 2022 Aug 12, 2022	SELL	$9.52 - $15.65 $148,902 - $244,781	-15,641 Reduced 38.0%	25,518 $311,000
Q1 2022 May 16, 2022	BUY	$13.24 - $20.24 $443,871 - $678,546	33,525 Added 439.15%	41,159 $590,000
Q4 2021 Feb 08, 2022	BUY	$15.44 - $27.32 $72,429 - $128,158	4,691 Added 159.4%	7,634 $150,000
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $18,526 - $31,047	895 Added 43.7%	2,943 $63,000
Q2 2021 Sep 13, 2021	BUY	$18.58 - $25.37 $38,051 - $51,957	2,048 New	2,048 $52,000

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Janux Therapeutics, Inc. Transaction History